详情页

当前位置：首页 > 详情页

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

3| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究单位： [1]Zai Lab (Shanghai) Co., Ltd. [2]Beijing Cancer Hospital Beijing, Beijing, China [3]Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China [4]Cancer Hospital Chinese Academy of Medical Science Beijing, Beijing, China [5]Hospital, Academy of Military Medical Sciences Beijing, Beijing, China [6]Peking union medical college hospital Beijing, Beijing, China [7]Fujian Cancer Hospital Fuzhou, Fujian, China [8]Nanfang Hospital Guangzhou, Guangdong, China [9]The first affiliated hospital of Guangzhou medical school Guangzhou, Guangdong, China [10]The first affiliated hospital of Guangxi Medical University Nanning, Guangxi, China [11]Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China [12]Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China [13]Henan Cancer Hospital Zhengzhou, Henan, China [14]The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China [15]Union hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China [16]Hunan Cancer Hospital Changsha, Hunan, China [17]The second xiangya hospital of central south university Changsha, Hunan, China [18]Nanjing General Hospital Nankín, Jiangsu, China [19]Nantong Tumor Hospital Nantong, Jiangsu, China [20]The first affiliated hospital of Nanchang University Nanchang, Jiangxi, China [21]The Second Affiliated hospital of Nanchang University Nanchang, Jiangxi, China [22]The First Hospital of Jilin University Changchun, Jilin, China [23]Jinzhou Central Hospital Jinzhou, Liaoning, China [24]China shenyang chest hospital Shenyang, Liaoning, China [25]Liaoning Cancer Hospital & Institute Shenyang, Liaoning, China [26]Lin Yi Cancer Hospital Linyi, Shandong, China [27]Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China [28]Shanghai Chest Hospital, Shanghai Jiao Tong University Shanghai, Shanghai, China [29]Tangdu Hospital Xi'an, Shanxi, China [30]Xinjiang Cancer Hospital Ürümqi, Xinjiang, China [31]Second Affiliated Hospital, Zhejiang University Hangzhou, Zhejiang, China [32]Zhejiang cancer hospital Hangzhou, Zhejiang, China [33]First Affiliated Hospital, Zhejiang University Hanzhou, Zhejiang, China [34]Anhui Provincal Hospital Hefei, Anhui, China

研究目的：

Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-based chemotherapy in patients with extensive-stage disease small cell lung cancer (ED-SCLC) to evaluate the efficacy and safety.